The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.
Suppliers are touting a deeper level of analysis, in some cases bypassing the market-research function and reaching the highest levels of their pharma clients.
The data and analytics giant is looking to launch an IPO. The company, which is the subject of an antitrust suit, said in its prospectus that it anticipates future acquisitions.
Mid-stage data show the drug, romosozumab, was associated with significant increases in bone mineral density compared to Lilly's Forteo and off-patent Fosamax.
The first on-demand way to tap the influencer community in healthcare went live today, and results of a real-world test show it has the potential to accelerate the research process.
Doctors shared their information preferences with CMI/Compas, revealing ways marketers can better pace their communications to max out channels.
IMS Health has acquired Seattle-based software-as-a-service (SaaS) company Appature, the firms are expected to announce today.
An ePharma Summit panel of physicians takes the sheen off new marketing initiatives by telling pharmas they find them useless.
A Merck study bolsters FDA's case for requiring that TV ads for prescription drugs present risks in text as well as the voiceover.
Seattle-based Appature has signed up several healthcare marketing agencies and business service firms to use its cloud-based relationship marketing platform.
Pharma companies are starting down the Big Data path but are trying to identify the business questions best suited to new analytic techniques.
An analysis of a cross-section of the pharma industry shows budgets of pharmaceutical marketing research teams are starting to recover from 2008 lows.
IMS has added claims data to its real-world evidence (RWE) platform, but can it satisfy industry's demand for RWE as well as a payer can?
Data show detailing pressure and pharmaceutical rep access are still much higher in primary care than in other specialties.
Lippincott builds out its Nursing Advisor and WorldOne adds a patient-insight component.
Double Helix, a healthcare consultancy that operates across three continents, was bought by Interpublic Group's McCann Health, the network said Monday.
A Mumbai-based pharma custom manufacturing firm is buying the parent company of Manhattan Research.
Symphony Technology Group, a private equity firm, acquired the healthcare analytics business of Wolters Kluwer, the companies said.
Genentech is thinking outside the traditional focus group to understand patients, helping address the long-standing business challenges of adherence and brand preference, the firm says.
FDA issues may deter drugmakers from engaging in social media, but that's no excuse to ignore what audiences are saying on these platforms, say pharma and device firms.
Responding to what it calls an "acute need" among clients for market access counsel, GfK is buying Bridgehead International, a consultancy with offices here and abroad.
Novartis named Brian McNamara as division head of OTC, replacing J&J veteran Naomi Kelman, who spent a year in the role.
Quite a few states have moved to shield marketing research from regulation. The Supreme Court's ruling on healthcare reform could spur new threats.
Privately held inVentiv Health will acquire two of SDI Health's audit businesses worth under $15 million, according to company statements. IMS Health agreed to divest the units when regulators approved its purchase of SDI last year.
AstraZeneca has enlisted data supplier IMS Health in an effort to collect evidence on how its treatments are doing outside of controlled clinical trials, firms said.
Physicians Interactive (PI) and WorldOne formed an exclusive strategic alliance to merge their US-based healthcare marketing research panels, firms said.
Two powers of the marketing research arena—Epocrates and M3—partnered today to create what they claim is the world's largest verified physician and healthcare provider panel.
Two potential blockbusters in the pharma pipeline took another step toward reaching market, as US regulatory authorities assigned PDUFA dates for Gilead Sciences' Quad pill and for Pfizer's tofacitinib.
Vertex's drug for treating hepatitis C virus, Incivek (telaprevir), is on course to smash the previous record for the biggest revenue-generating drug launch ever, says an analyst firm.
Federal regulators gave IMS Health the go-ahead to buy SDI Health, and IMS's parent company must now divest two SDI product lines.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.